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Abstract We report the isolation of a novel pardaxin isoform
from the toxic secretion of the Red Sea Moses sole (Pardachirus
marmoratus). Mass spectrometrical analysis of the newly
purified peptide revealed a different primary structure compared
to the previously known pardaxin isoforms. Sequence analysis
disclosed an aspartic acid residue instead of glycine at position 31
of the new isoform. According to the novel sequence, a synthetic
Asp-31-peptide was compared with the native compound as well
as with synthetic Gly-31-pardaxin. The isolated Asp-31-pardaxin
isoform and its synthetic analog exhibited identical elution
properties during reverse-phase HPLC, as well as similar dose-
dependent lytic effects on human erythrocytes at a concentration
of 1036 to 1035 M. The hemolytic activity of Asp-31-pardaxins
was lower than that of Gly-31-pardaxin and no synergistic effect
between these peptides was found. The additional negative charge
introduced by Asp-31 is likely to affect the selectivity of pardaxin
pores towards a variety of ions.
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1. Introduction
Sole ¢sh of the genus Pardachirus produce an exocrine se-
cretion from epithelial glands located at the base of the dorsal
and anal ¢ns. This secretion contains toxic components that
play an important role in the defense of predatory ¢sh [1].
Beside aminoglycosteroids [2], peptides, known as pardaxins
[3], represent the major components of the secretion [4^6].
Pardaxins have been shown to form voltage-dependent ion
channels [7^9] at low concentrations [5^14] in a variety of
arti¢cial membranes and cytolysis at high concentrations
[5,11]. The membranal activity of pardaxins, binding, inser-
tion and rearrangement for pore formation, is dependent on
the K-helix content as well as the intramolecular interaction
between the amino- and carboxy-terminal domains [10,15].
Thus, this peptide family is structurally and functionally re-
lated to other membrane-associated peptides, e.g. cecropins
[16], magainins [17] and melittin [18]. To date, pardaxins
have been isolated and characterized from the western Paci¢c
Peacock sole, P. pavoninus (P1, P2 and P3) [4], and the Red
Sea Moses sole, P. marmoratus [5,6]. We refer to the P. mar-
moratus pardaxin described by Shai et al. [6] as pardaxin P4.
All known pardaxins contain one single peptide chain com-
posed of 33 amino acids and show a high tendency of aggre-
gation in aqueous solution [5,9]. Their sequences are very
homologous, di¡ering only at positions 5, 14 or 31 (Fig. 1).
The membranal e¡ects of pardaxins are rather sensitive to
structural variations such as the net charge, attached side
chains, the stereochemistry of K-carbons and chain truncation
[10,11,19].
In the context of our work on the internalization of immu-
noglobulin conjugates [20] for the treatment of experimental
lymphomas [21^23], we became interested in the interaction of
pardaxin conjugates with plasma membranes. In this study,
we report the isolation of a novel pardaxin isoform (P5) from
P. marmoratus. The primary structure of the native peptide
has been determined by amino acid sequencing, endoprotei-
nase cleavage and mass spectrometric techniques. To verify
the identity of the novel peptide, it was compared with the
corresponding synthetic peptides by reverse-phase HPLC and
a hemolysis assay.
2. Material and methods
2.1. Puri¢cation of pardaxin isoform
Twelve specimens of P. marmoratus, caught in the Gulf of Eilat,
were supplied by the Interuniversity Marine Biology Institute of Eilat,
Israel. Their secretions were collected manually by gentle hand pres-
sure of the glands. The secretions of four ¢sh were combined and the
ensuing three batches lyophilized. The lyophilisates were extracted
with water and the aqueous extracts desalted on Sephadex G25 (Phar-
macia) and separated by gel ¢ltration on Sephadex G100 as described
[5] and ¢nally lyophilized. The yield of dry material was about 20 mg
per ¢sh. For analytical purposes, further puri¢cation of 100 Wg sam-
ples was carried out by reverse-phase HPLC on a Nucleosil C18 PPN
column (Macherey and Nagel, 5 Wm, 100 Aî , 2.1U250 mm) using a
linear gradient from 10^80% solvent B in 45 min (solvent A, 0.5%
TFA; solvent B, 0.1% TFA in acetonitrile/water 4:1; £ow rate, 0.2 ml;
UV detection at 215 nm). Larger amounts of pardaxin fractions
(20^40 mg) were puri¢ed using a Vydac C18 column (the Separations
Group, 10 Wm, 300 Aî , 20U250 mm; £ow rate, 8 ml/min; UV detec-
tion at 230 nm).
2.2. Mass spectrometry of pardaxin
Electrospray mass spectrometry (ES-MS) was performed on an API
III triple stage quadrupole mass spectrometer (SCIEX, Perkin-Elmer)
equipped with the high pressure collision cell. The articulated ion
spray was operated at 5 kV. Mass spectra of pardaxins, which were
dissolved in 50% acetonitrile containing 0.5% formic acid, were ob-
tained by £ow infusion at 5 Wl/min and by scanning the ¢rst quadru-
pole from m/z 400 to 2400 at a sampling rate of 3 s/spectrum with one
data point per 0.5 mass units. For sequence analysis by collision-
induced dissociation (CID) [24], the ¢rst quadrupole was set to the
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m/z value of the single-charged peptide as determined before. Argon
was used as collision gas at a collision energy of 20 eV. The second
mass spectrometer was scanned from 10 m/z to the m/z value deter-
mined for the single-charged ion. At least 20 spectra were sampled.
The peptide map obtained by endoproteinase treatment of pardaxin
P5 was analyzed by coupling the liquid chromatography separation to
the mass spectrometer (LC/MS) using a double syringe pump (140B,
Perkin Elmer/ABI) operated at a £ow rate of 20 Wl/min. A variable
UV detector (765, Perkin Elmer/ABI) equipped with a capillary U-
£ow cell (LC Packings) was used to detect UV absorbance at 220 nm.
The eluent was infused into the ion spray without splitting. The C18
column used for LC/MS analysis was from YMC (ODS-AQ, 1U10
mm, 120 Aî , 3 Wm). A gradient with solvent A, 0.8% TFA in water,
and B, 0.06% TFA in 80% acetonitrile, from 10% B in A to 70% B in
A over 60 min was used for the separation.
2.3. Enzymatic cleavage and peptide sequencing of pardaxin isoform P5
Enzymatic degradation of pardaxin was performed by standard
treatment with endoproteinase Lys-C (Boehringer Mannheim) at an
enzyme to peptide ratio of 1:50 in 250 Wl 0.1 M NH4HCO3 for 24 h at
37‡C (pH 8.2). The solution was freeze-dried and dissolved in 50 Wl
0.1% TFA. The resulting peptide mixture was separated by C18 LC/
MS analysis (0.5U100 mm) using a double syringe pump at a £ow
rate of 5 Wl/min. UV absorbance was determined at 215 nm. Fractions
were collected automatically every minute. Peptides were directly ap-
plied to polybrene-coated glass ¢ber ¢lters for amino-terminal se-
quencing which was performed on a 494 Procise sequencer (Perkin
Elmer/ABI) using standard conditions as recommended by the man-
ufacturer.
2.4. Synthesis of pardaxin peptides
Pardaxins P4 and P5 were synthesized on a 433A peptide synthe-
sizer (Perkin Elmer/ABI) using standard Fmoc solid phase chemistry
[25] on a preloaded Fmoc-Glu(OtBu)-TentaGel S PHB resin (Rapp
Polymere). Fmoc amino acids were coupled in the presence of 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium (HBTU) and diisopro-
pylethylamine (DIEA) in N-methylpyrrolidinone (NMP) for 30 min.
Fmoc groups were cleaved with 20% piperidine in NMP. For depro-
tection and resin cleavage, the peptidyl resin was treated with a fresh
mixture of TFA/ethanedithiol/water (94:3:3) for 2.5 h. After ¢ltra-
tion, the peptides were precipitated by addition of cold tert-butylme-
thylether and lyophilized from 10% acetic acid. Thereafter, the crude
peptides were puri¢ed by reverse-phase HPLC (Vydac C18, 10 Wm,
300 Aî , linear gradient from 10^100% solvent B in 60 min; solvent B,
0.1% TFA/water; solvent B, 0.1% TFA in acetonitrile/water 4:1; £ow
rate, 8 ml/min; UV detection at 230 nm). The purity and identity of
pardaxins P4 and P5 were checked by analytical HPLC and sequence
analysis. The molecular masses were determined by ES-MS and cal-
culated from [M+2H]2 : P4, 3323.9 (calc., 3323.9); P5, 3381.2 (calc.,
3381.9).
2.5. Hemolysis assay
Venous blood (10 ml) was drawn from a healthy male adult person,
mixed with 1 ml 10% sodium citrate bu¡er, and then centrifuged. The
pellet obtained was washed three times with cold isotonic NaCl. For
calibration, various numbers of erythrocytes (between 106 and 108)
were suspended in 1 ml of 0.2% SDS. For the hemolysis assay of the
pardaxins, 108 erythrocytes were incubated in 1 ml peptide solution at
concentrations between 1037 and 1035 M at 25 or 37‡C for 30 min.
The erythrocyte suspensions were centrifuged, and the hemoglobin
absorption of the supernatants was measured at 550 nm. All data
points were obtained in quadruplicate; relative standard errors were
maximum 15%. The concentration of peptides used for this assay was
calculated according to their absolute peptide content as determined
by amino acid analysis. Pardaxin mixtures were tested in a molar
ratio.
3. Results and discussion
Two major compounds were separated by reverse-phase
HPLC puri¢cation of the secretion extract of P. marmoratus
(Fig. 2). Neither HPLC nor electrospray mass spectrometry
(ES-MS) revealed any signi¢cant di¡erence between the par-
daxins puri¢ed from the three batches, each containing the
pardaxin of four ¢sh. Furthermore, ES-MS analysis revealed
molecular weights of 4362.5 Da and 3382.6 Da for peaks 1
and 2, respectively, in contrast to the molecular weight of P.
marmoratus pardaxin P4 (3323.9 Da, Fig. 1) [6]. The estimated
yield per ¢sh was about 5 mg of peak 1 and 10 mg of peak 2.
Edman degradation of peak 1 did not generate any amino
acid, suggesting that this compound is a peptide with a pro-
tected N-terminal amino function. Since no leucine, but me-
thionine, histidine, tyrosine and aspartic acid/asparagine are
contained in this peptide, as detected by amino acid analysis,
its primary structure di¡ers considerably from that of pardax-
ins. Sequence analysis of peak 2 resulted in a partial amino
acid sequence which was in complete agreement with positions
1 to 25 of pardaxin P4. Interestingly, peak 2 contained a
shoulder with a slightly shorter retention time during HPLC
analysis (Fig. 2), but identical molecular weight as the main
part of peak 2. This e¡ect may be assigned to an oligomeri-
zation tendency in aqueous solution which was reported ear-
lier for pardaxins [10,15]. Further sequence analysis of the
isolated compound corresponding to peak 2 was carried out
after cleavage of the isolated peptide by endoproteinase Lys-
C. Three fragments were obtained and their molecular weights
and amino acid sequences determined by Edman degradation
and collision-induced dissociation (CID, Table 1, Fig. 2). The
molecular weights of two out of the three fragments were in
agreement with the sequence positions 1^16 of pardaxin P4
from P. marmoratus. The carboxy-terminal fragment with a
molecular weight of 1621 Da showed a di¡erence of +58 Da
compared with the corresponding fragment which should be
obtained from Lys-C digestion of pardaxin P4. This fragment
was further analyzed by CID [24], and a carboxy-terminal
sequence of ALSSSGDQE could be unambiguously assigned.
Fig. 3 shows the CID daughter spectrum of the ion [M+H]
with indicated fragment ions of the y-series. This carboxy-
terminal sequence of P5 was also con¢rmed by Edman deg-
radation of the separated fragment 3. In addition, amino acid
analysis showed that one Asp residue is contained in the iso-
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Fig. 1. Amino acid alignment of pardaxins. P1, P2 and P3 are from
P. pavoninus [4], P4 [6] and P5 are from P. marmoratus. Variable
residues are bold-faced.
Table 1
Analysis of peptide fragments obtained by endoproteinase Lys-C cleavage of P. marmoratus pardaxin P5
Fragment Sequence position Sequence detected MW calculated MW experimentalc
1 1^8 GFFALIPKa 892.1 893.0
2 9^16 IISSPLFKa 904.1 904.5
3 17^33 TLLSAVGSALSSSGDQEa;b 1621.7 1621.0
aEdman degradation, bcollision-induced dissociation (CID), celectrospray mass spectrometry (ES-MS).
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lated pardaxin. The exchange of Gly-31 of pardaxin P4 by
Asp is in exact accordance with the molecular weight di¡er-
ence between P4 and P5. Thus, the amino acid sequence of
pardaxin P5 identi¢ed and isolated from P. marmoratus is
di¡erent from pardaxin P4 [6] and represents a novel pardaxin
isoform.
To verify the sequence of the isolated pardaxin P5, we syn-
thesized a peptide according to the determined primary struc-
ture using Fmoc chemistry and compared this peptide chro-
matographically with the native compound. Fig. 4 reveals that
pardaxin P5 isolated from P. marmoratus eluted with a reten-
tion time identical to that of the synthetic peptide. In contrast
to the native P5, the synthetic pardaxin P5 gave a sharp peak
on HPLC analysis, indicating a di¡erent oligomerization ten-
dency. The sequence of the novel pardaxin P5 di¡ers by one
point mutation from the pardaxin P1 isolated from P. pavo-
ninus. The change Asp-31CGlu-31 would require a mutation
of the third base of the Asp-31 codon. In addition, a mutation
CCU, the ¢rst base of the Leu-5 codon of P1, would lead to
the sequence of P3, another pardaxin found in P. pavonius. In
contrast, no single point mutation of either P1, P3 or P5
would lead to P2. The pardaxin P2 is genetically closest to
P5, di¡ering in position 31 (AspCGly: CCA exchange of
the ¢rst base of the Leu-14 codon). The earlier published
report on the isolation of P. marmoratus pardaxin P4 con-
tained a sequence analysis by Edman degradation, but no
mass spectral analysis was provided [6]. It seems likely that
either a misinterpretation of Edman sequencing resulted in an
incorrect determination of the residue at position 31 or the
toxin puri¢ed at that time was of a di¡erent composition. We
suggest that the pardaxin isoform P4 may provide the muta-
tion gap between P5 and P2. It would be one point mutation
away from P5 (Asp-31CGly-31) and another point mutation
away from P2 (Leu-14CIle-14). However, the investigation of
this evolutionary structure-function relationship requires fur-
ther evaluation using other Pardachirus species.
To assess the biological activity of the native and synthetic
pardaxins, their hemolytic potency was quanti¢ed. At concen-
trations between 1036 and 1035 M, the isolated pardaxin P5
evoked a dose-dependent hemolysis (Fig. 5A). A similar dose-
response curve was obtained with synthetic P5, thus providing
indirect evidence for their structural identity. In contrast, par-
daxin P4 synthesized according to the published sequence [6]
had a four- to ¢ve-fold higher hemolytic activity. Correspond-
ing to the hemolytic potency, P5 was found to activate phos-
pholipase A2 [26] and to induce release of dopamine (data not
shown) [27] with a lower potency compared to P4. Peak 1
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Fig. 3. Collision-induced dissociation (CID) mass spectrum of the
single-charged ion [M+H] of fragment 3 (Table 1) obtained by en-
doproteinase Lys-C cleavage of peak 2. Successive peptide bond
cleavage of amino acid residues starting at the carboxy terminus ac-
cording to the y-series is indicated.
Fig. 4. HPLC comparison of native pardaxin P5 and the corre-
sponding synthetic peptide. Upper trace: native peptide; middle
trace: synthetic P5; bottom trace: coelution of equivalent amounts
of native and synthetic P5. HPLC was carried out using a Nucleosil
C18 PPN column with a linear gradient of 50^100% bu¡er B in 60
min.
Fig. 2. Analytical reverse-phase HPLC of the toxic secretion of P.
marmoratus. Chromatography was carried out as described in Sec-
tion 2. Peaks 1 and 2 were collected and further characterized. The
inset shows a stretching of peak 2 which corresponds to pardaxin
P5.
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obtained from pardaxin puri¢cation (Fig. 2) as well as a de-
rivative of native P5 isoform obtained by peracylation of pri-
mary amino groups with 2-(4P-hydroxyphenyl)acetic acid were
inactive. The lack of hemolytic activity of Acyl3-P5 can be
explained by the complete loss of positive charges thereby
impairing the amphiphatic character that enables pardaxins
to aggregate and to form pores in cell membranes [14]. The
occurrence of structurally closely related pardaxins in the
same species may cause a synergistic physiological e¡ect be-
tween these peptides. To examine this hypothesis, we tested
the hemolytic activity of mixtures of synthetic pardaxins P4
and P5 in di¡erent molar ratios (Fig. 5B). The results of this
assay demonstrate that the hemolytic e¡ect of pardaxin mix-
tures is unambiguously additive, but not synergistic. Likewise,
peptide mixtures containing di¡erent molar amounts of native
P4 and synthetic P5 caused additively a leakage of cytosolic
lactate dehydrogenase (LDH) [28], thus con¢rming the results
obtained from the hemolysis assay (data not shown). In sum-
mary, the novel pardaxin P5 has a similar e⁄cacy compared
to P4, but a signi¢cant lower potency. There are no indica-
tions of a synergistic e¡ect between these peptides. The di¡er-
ent hemolytic activities of P4 and P5 may be due to di¡erences
in either their charge or their secondary structure. We pre-
dicted that the carboxy terminus is the ¢lter of the pardaxin
channel [14]. This ¢lter is responsible for the relative selective
permeability for cations. Therefore, an additional negative
charge at position 31 might increase the permeability ratio
for ions of pardaxin pores. Considering the presence of a
variety of di¡erent pardaxins in the same species, one may
speculate that this re£ects a molecular resource which allows
the ¢sh to adjust to environmental changes a¡ecting food
supply or the appearance of new predators. Other animals
such as snails of the species Conus are also provided with
di¡erent structurally closely related toxic peptides causing
an enhanced e¡ectiveness for a defensive or o¡ensive purpose.
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